Zhao, Yanqiu

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 122

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

Li, Z., Dang, X., Huang, D., Jin, S., Li, W., Shi, J., Wang, X., Zhang, Y., Song, Z., Zhang, J., et al. (2024) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 49

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 42

Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study

Li, W., Xiong, A., Yang, N., Fan, H., Yu, Q., Zhao, Y., Wang, Y., Meng, X., Wu, J., Wang, Z., et al. (2024) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 40

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.

Lu, S., Zhang, Q., Meng, X., Sun, Y., Xiong, H. H., Lv, D., Wang, X., Wu, L., Dong, X., Ji, Y., et al. (2024) · Journal of Clinical Oncology

Cancer therapeutics and mechanismsMonoclonal and Polyclonal Antibodies Research

Cited by 1